CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
BI 1015550 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05550636
NCT05550636Phase 1Completed
CompareCT.gov

The Effect of Multiple Oral Doses of BI 1015550 on Metabolism of Midazolam Administered Orally in Healthy Male Subjects (Open-label, Two-period Fixed Sequence Design Trial)

Boehringer Ingelheim·interventional·Posted Sep 22, 2022·Updated Dec 1, 2025

In Brief

A Phase 1 clinical trial evaluating BI 1015550 and midazolam for Healthy. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The main objective of this trial is to investigate the induction effect of multiple doses of BI 1015550 on the pharmacokinetics of the sensitive CYP3A4 substrate midazolam.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedSep 22, 2022
Enrollment StartOct 11, 2022
Primary CompletionDec 19, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.8 years ago

Interventions

BI 1015550drug

BI 1015550

midazolamdrug

midazolam